scholarly journals First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia

2011 ◽  
Vol 3 (3) ◽  
pp. 208-216 ◽  
Author(s):  
Shih-Tzer TSAI ◽  
Faruque PATHAN ◽  
Linong JI ◽  
Vincent Tok Fai YEUNG ◽  
Manoj CHADHA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Real World ◽  
Basal Insulin ◽  
Real World Setting

scholarly journals Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study

2018 ◽  
Vol 89 ◽  
pp. 37-42 ◽  
Author(s):  
Diego Bellido ◽  
Pablo Abellán ◽  
José Manuel Ruiz Palomar ◽  
Rogelio Álvarez Sintes ◽  
Andreu Nubiolae ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Therapy ◽  
Real World ◽  
Basal Insulin ◽  
Real World Setting

scholarly journals Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study

2019 ◽  
Vol 7 (1) ◽  
pp. e000884 ◽  
Author(s):  
Reema Mody ◽  
Qing Huang ◽  
Maria Yu ◽  
Hiren Patel ◽  
Xian Zhang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Real World ◽  
Basal Insulin ◽  
Linear Models ◽  
Statistical Significance ◽  
Economic Outcomes ◽  
Analysis Of Covariance ◽  
Real World Setting ◽  
Baseline Characteristics

AimsTo report 1-year clinical and economic outcomes from the retrospective DISPEL (Dulaglutide vs Basal InSulin in Injection Naïve Patients with Type 2 Diabetes: Effectiveness in ReaL World) Study.Materials and methodsThis observational claims study included patients with type 2 diabetes (T2D) and ≥1 claim for dulaglutide or basal insulin between November 2014 and April 2017 (index date=earliest fill date). Propensity score matching was used to address treatment selection bias. Change from baseline in hemoglobin A1c (HbA1c) was compared between the matched cohorts using analysis of covariance; diabetes-related costs were analyzed using generalized linear models.ResultsMatched cohorts (903 pairs total; 523 pairs with complete cost data) were balanced in baseline characteristics with mean HbA1c 8.6%, mean age 54 years. At 1 year postindex, dulaglutide patients had significantly greater reduction in HbA1c than basal insulin (−1.12% vs −0.51%, p<0.01), lower medical costs ($3753 vs $7604, p<0.01), higher pharmacy costs ($9809 vs $6175, p<0.01), and similar total costs ($13 562 vs $13 779, p=0.76). Medical and total costs per 1% HbA1c reduction were lower for dulaglutide than basal insulin (medical: $3128 vs $12 673, p<0.01; total: $11 302 vs $22 965, p<0.01), while pharmacy costs per 1% HbA1c reduction were lower without reaching statistical significance ($8174 vs $10 292, p=0.15).ConclusionsIn this real-world study, patients with T2D initiating dulaglutide demonstrated greater HbA1c reduction compared with those initiating basal insulin. Although total diabetes-related costs were similar, the total diabetes-related costs per HbA1c reduction were lower for dulaglutide, highlighting the importance of evaluating effectiveness along with the economic impact of medications.

scholarly journals The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real‐world setting

2019 ◽  
Vol 21 (6) ◽  
pp. 1429-1436 ◽  
Author(s):  
Luigi F. Meneghini ◽  
Didac Mauricio ◽  
Emanuela Orsi ◽  
Nebojsa M. Lalic ◽  
Anna M.G. Cali ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Real World ◽  
Basal Insulin ◽  
Unmet Need ◽  
Real World Setting

scholarly journals Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes

2018 ◽  
Vol 20 (9) ◽  
pp. 2093-2102 ◽  
Author(s):  
Jetty A. Overbeek ◽  
Edith M. Heintjes ◽  
Eline L. Huisman ◽  
Christian K. Tikkanen ◽  
Arnout W. van Diermen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Real World ◽  
Basal Insulin ◽  
Weight Control ◽  
Clinical Effectiveness ◽  
Obese People ◽  
Real World Setting

Evaluation of Treatment Persistence in Individuals with Type 2 Diabetes in a Real-World Setting

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 135-OR
Author(s):  
WILLIAM T. CEFALU ◽  
TAMARA DARSOW ◽  
MATT PETERSEN ◽  
LIISA PALMER ◽  
ELLEN THIEL ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Real World ◽  
Treatment Persistence ◽  
Real World Setting
Sign in / Sign up

Export Citation Format

Share Document